People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viracta Therapeutics, INC. | — | Biotechnology | Series C | $164.6M | $2.1B | 2010 |
| Heron Therapeutics, Inc. /De/ | — | Biotechnology | Series C | $117.2M | $382.4M | 2009 |
| Pathway Therapeutics, Inc. | — | Biotechnology | Series A | $16.9M | $14.5M | 2012 |
| ARYx Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.4M | $76.6M | 2009 |
Paul Goddard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Goddard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| CRAIG JOHNSON | 1 | 16 |
| Patrick Soon-Shiong | 1 | 16 |
| Ivor Royston | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Mark Perry | 1 | 6 |
| Robert Zerbe | 1 | 5 |
| James Woody | 1 | 4 |
| Roger Pomerantz | 1 | 4 |
| Barry Simon | 1 | 3 |
| Joshua Funder | 1 | 3 |
| Lars G. Ekman | 1 | 3 |
| Kevin Tang | 1 | 3 |
| Armen Shanafelt | 1 | 3 |
| Mark Harvey | 1 | 3 |
| James N. Woody | 1 | 3 |
| Kevin Kotler | 1 | 3 |
| John Barr | 1 | 3 |
| Ronald Berenson | 1 | 3 |
| Frederick Dotzler | 1 | 3 |
| Nick Simon | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.